Details of the Drug

General Information of Drug (ID: DMYTTBK)

Drug Name

CX2029

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1/2	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody drug conjugate

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transferrin receptor protein 1 (TFRC)	TT8MG4S	TFR1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03543813) A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). U.S.National Institutes of Health.
2	Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336.